Mirtazapin Heumann (Mirtazapine)

Mirtazapine, the active ingredient in Mirtazapin Heumann, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as an oral tablet for oral use. It is indicated for the treatment of major depressive disorder in adults. GNH USA supplies Mirtazapin Heumann as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirtazapine is used within the antidepressant therapeutic class to address depressive disorders. - Major depressive disorder: reduces depressive symptoms and improves mood in adult patients.

Mirtazapine may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Sedation or drowsiness - Increased appetite and weight gain - Dry mouth - Constipation - Dizziness - Fatigue

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Serotonin syndrome, especially with other serotonergic agents - Suicidal thoughts or behavior, particularly early in treatment - Severe hypotension or syncope

Before initiating therapy, clinicians should consider several safety factors. - Pregnancy: safety not established; use only if potential benefit justifies risk. - Breastfeeding: avoid unless benefits outweigh potential infant exposure. - Elderly patients: monitor for excessive sedation and fall risk. - Concomitant MAO inhibitors: avoid due to risk of hypertensive or serotonin syndrome. - Suicidal ideation: closely monitor especially during the first weeks of treatment. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and light.

Mirtazapine can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis or serotonin syndrome. - Other serotonergic agents (SSRIs, SNRIs, tramadol, linezolid): increased risk of serotonin syndrome. - Strong CYP2D6 inhibitors (paroxetine, fluoxetine): may raise mirtazapine plasma levels.

Moderate Interactions (Monitor Closely): - CNS depressants (alcohol, benzodiazepines, opioids): additive sedation. - Antihistamines: may enhance drowsiness. - Anticholinergic drugs: potential for increased dry mouth and constipation.